Elevated liver transaminases among patients with psychiatric disorders.

IF 2.1 3区医学 Q3 PHARMACOLOGY & PHARMACY International Clinical Psychopharmacology Pub Date : 2024-05-01 Epub Date: 2024-03-25 DOI:10.1097/YIC.0000000000000514

Eman Ali, Mona Ahmed Abdel Maksoud, Shaymaa M Arafa, Doaa Ibrahim, Ahmed El-Sayed Hassan, Omnia Awwad, Ahmed M Elbeltagy, Essam Elmahdi, Reham Elgarhi, Ahmed Embaby

{"title":"Elevated liver transaminases among patients with psychiatric disorders.","authors":"Eman Ali, Mona Ahmed Abdel Maksoud, Shaymaa M Arafa, Doaa Ibrahim, Ahmed El-Sayed Hassan, Omnia Awwad, Ahmed M Elbeltagy, Essam Elmahdi, Reham Elgarhi, Ahmed Embaby","doi":"10.1097/YIC.0000000000000514","DOIUrl":null,"url":null,"abstract":"<p><p>Hepatocyte injury is assessed by serum aspartate transaminase and alanine transaminase estimation. In psychiatric populations, antipsychotic drugs (AD) are culprit in hepatic dysfunction. To assess transaminitis among psychiatric patients treated by AD. This cross-sectional study was conducted in Zagazig University Hospitals in Egypt, from December 2022 to February 2023. A total of 135 adult patients aged ≥ 18 years, were diagnosed with psychiatric disorders after exclusion of patients receiving any hepatotoxic drugs, viral hepatitis, having chronic liver or kidney diseases, diabetes mellitus, mental retardation, and pregnant females. Among the 135 patients, 104 (77.0%) were males. Their age was 32 ± 9, The most popular used class of AD was atypical AD 84 (62.2%). The overall incidence of transaminitis among patients receiving AD was 23/135 (17.04%) of patients; 13 (56.5%) were on atypical AD compared to 10 (43.5%) patients receiving combined AD, without any statistically significant difference. The use of AD in patients with psychiatric disorders is potentially safe with minimal transaminitis (<one-fold elevation). However, baseline and regular monitoring of serum aminotransferase is recommended during treatment.</p>","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"195-200"},"PeriodicalIF":2.1000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Clinical Psychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/YIC.0000000000000514","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/25 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Hepatocyte injury is assessed by serum aspartate transaminase and alanine transaminase estimation. In psychiatric populations, antipsychotic drugs (AD) are culprit in hepatic dysfunction. To assess transaminitis among psychiatric patients treated by AD. This cross-sectional study was conducted in Zagazig University Hospitals in Egypt, from December 2022 to February 2023. A total of 135 adult patients aged ≥ 18 years, were diagnosed with psychiatric disorders after exclusion of patients receiving any hepatotoxic drugs, viral hepatitis, having chronic liver or kidney diseases, diabetes mellitus, mental retardation, and pregnant females. Among the 135 patients, 104 (77.0%) were males. Their age was 32 ± 9, The most popular used class of AD was atypical AD 84 (62.2%). The overall incidence of transaminitis among patients receiving AD was 23/135 (17.04%) of patients; 13 (56.5%) were on atypical AD compared to 10 (43.5%) patients receiving combined AD, without any statistically significant difference. The use of AD in patients with psychiatric disorders is potentially safe with minimal transaminitis (

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

精神疾病患者肝转氨酶升高。

通过血清天冬氨酸转氨酶和丙氨酸转氨酶评估肝细胞损伤。在精神病患者中，抗精神病药物（AD）是导致肝功能障碍的罪魁祸首。评估AD治疗的精神病患者的转氨酶。这项横断面研究于2022年12月至2023年2月在埃及扎加齐格大学医院进行。共有135名年龄≥18岁的成年患者，在排除接受任何肝毒性药物、病毒性肝炎、患有慢性肝病或肾病、糖尿病、智力迟钝和孕妇后，被诊断为精神障碍。135例患者中，男性104例（77.0%）。他们的年龄是32岁 ± 9、最常用的AD类别为非典型AD 84（62.2%），接受AD治疗的患者中转氨酶的总发生率为23/135（17.04%）；13例（56.5%）为非典型AD患者，而10例（43.5%）为合并AD患者，无任何统计学显著差异。AD在精神障碍患者中的使用可能是安全的，只要最小限度地使用氨甲酰氨基转移酶(

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

International Clinical Psychopharmacology 医学-精神病学

CiteScore

4.40

自引率

23.10%

发文量

审稿时长

>12 weeks

期刊介绍： International Clinical Psychopharmacology provides an essential link between research and clinical practice throughout psychopharmacology. It reports on studies in human subjects, both healthy volunteers and patients, which relate the effects of drugs on psychological processes. A major objective of the journal is to publish fully refereed papers which throw light on the ways in which the study of psychotropic drugs can increase our understanding of psychopharmacology. To this end the journal publishes results of early Phase I and II studies, as well as those of controlled clinical trials of psychotropic drugs in Phase II and IV. Other topics covered include the epidemiology of psychotropic drug prescribing and drug taking, the sociology of psychotropic drugs including compliance, and research into the safety and adverse effects of these compounds.